At the time of writing, Humacyte Inc [HUMA] stock is trading at $1.53, up 4.08%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The HUMA shares have gain 8.51% over the last week, with a monthly amount drifted -18.62%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Humacyte Inc [NASDAQ: HUMA] stock has seen the most recent analyst activity on August 27, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $3.50. On December 20, 2024, H.C. Wainwright reiterated its Buy rating and revised its price target to $15 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $6 on December 11, 2023. Piper Sandler upgraded its rating to a Neutral and raised its price target to $3.50 on August 14, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on June 22, 2023, and assigned it a price target of $6. In a note dated May 16, 2022, Piper Sandler downgraded an Underweight rating on this stock and revised its target price from $10 to $4.
For the past year, the stock price of Humacyte Inc fluctuated between $1.15 and $6.77. Currently, Wall Street analysts expect the stock to reach $3.5 within the next 12 months. Humacyte Inc [NASDAQ: HUMA] shares were valued at $1.53 at the most recent close of the market. An investor can expect a potential return of 128.76% based on the average HUMA price forecast.
Analyzing the HUMA fundamentals
Gross Profit Margin for this corporation currently stands at 0.05% with Operating Profit Margin at -13.82%, Pretax Profit Margin comes in at -7.29%, and Net Profit Margin reading is -7.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is 3.08 and Total Capital is -0.94. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 3.73.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Humacyte Inc [NASDAQ:HUMA] has a current ratio of 2.45. Further, the Quick Ratio stands at 1.93, while the Cash Ratio is 1.8. Considering the valuation of this stock, the price to sales ratio is 295.50, the price to book ratio is 59.03.
Transactions by insiders
Recent insider trading involved Dougan Brady W, Director, that happened on Aug 19 ’25 when 1.1 million shares were sold. Director, Dougan Brady W completed a deal on Aug 18 ’25 to sell 0.55 million shares. Meanwhile, Director Dougan Brady W sold 0.59 million shares on Aug 20 ’25.
